



The Prevalence of Colonization with Carbapenem-resistant *Enterobacteriaceae*, *Escherichia coli*, *Klebsiella* and *Enterobacter*, and Related Risk Factors in Children

Shahnaz Armin¹, Leila Azimi¹, Ghazal Shariatpanahi^{2,*}, Armin Shirvani³ and Nasim Almasian Tehrani⁴

¹Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran

³Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴Department of Microbiology and Microbial Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran. Email: gshariatpanahi@yahoo.com

Received 2022 December 26; Revised 2023 March 19; Accepted 2023 March 23.

Abstract

Background: Carbapenems are broad-spectrum antibiotics used to treat the family of gram-negative *Enterobacteriaceae*, especially those that are resistant to first-line antibiotics. Because these drugs are usually prescribed as the last line of treatment, resistance to these antibiotics carries irreparable risks to treatment systems, and screening high-risk individuals in medical centers and using infection control measures are critical strategies for eliminating them.

Objectives: We investigated the prevalence of colonization of different strains of *Enterobacteriaceae*, *Klebsiella*, *Enterobacter*, and *Escherichia coli* and their risk factors in hospitalized children.

Methods: In this descriptive cross-sectional study, stool samples were taken from patients during the first 48 hours of hospitalization in a tertiary children's hospital and were cultured on Makcanki culture medium or EMB. Cultured *Enterobacteriaceae* samples were transferred to Müller-Hinton agar medium, and their antibiotic susceptibility was evaluated with meropenem and imipenem discs by disc diffusion method. In the next step, five common carbapenemase genes, including (*VIM*, *IMP*, *OXA-48*, *NDM-1*, and *SPM-1*) were examined by PCR method and reported accordingly.

Results: Two hundred and ninety-five stool samples were examined, of which 242 (82%) samples were cultured positively with *Enterobacteriaceae*. The prevalence of carbapenem resistance was reported to be 37% among 295 samples using the phenotypic method. Resistance rates were high in patients with a history of antibiotic use, with frequent hospitalizations (more than two episodes in the last six months), and in patients with an underlying disease) malignancy, GI diseases, immunodeficiency, neurologic diseases such as cerebral palsy and epilepsy, endocrine diseases. Most of the genes found were *OXA-48*, followed by *IMP* and *VIM*. *NDM-1* was found in 3 samples, and *SPM* was not found in any of the samples. In 13% of resistant samples, more than one carbapenemase gene was found.

Conclusions: The results of this study showed that the frequency of carbapenem resistance in stools colonized with *Enterobacteriaceae* is high in our patients. On the other hand, the presence of carbapenemase genes in these bacteria, which are located on the plasmids that can be rapidly spread in the hospital environment, is an alarm for the hospital infection control committee to take preventive measures in order to prevent the spread of these bacteria in the hospital.

Keywords: *Enterobacteriaceae*, Carbapenem, Screening, Colonization

1. Background

Carbapenems are the most broad-spectrum beta-lactam antibiotics against gram-negative bacteria. Most beta-lactamases cannot break down these antibiotics. As a result, medications in this class are employed as the final line of defense against gram-negative bacteria resistant to other antibiotics (1). Resistance to several

antibiotics has been reported in the *Enterobacteriaceae* family in recent decades, forcing clinicians to administer carbapenems as a last resort. Carbapenem resistance was not discovered in the United States until the year 2000. Unlike methicillin resistance in *Staphylococcus aureus* species, which occurs and is caused by a single mechanism, carbapenem resistance in *Enterobacteriaceae* occurs in several members of this family and is caused by various

distinct mechanisms (2, 3). Among the *Enterobacteriaceae* family, *Klebsiella pneumoniae* and *Escherichia coli* species produce more carbapenemase enzymes. Carbapenem-resistant *Enterobacteriaceae* (CRE) show different resistance characteristics that depend entirely on genetic elements and the type of carbapenemase they produce. The carbapenemase-producing *Enterobacteriaceae* family has developed resistance that can easily be transmitted between them and other species. The most dominant type of carbapenemase created worldwide is related to the bacterium *K. pneumoniae*, which is associated with the blaKPC gene. Other identified carbapenemases related to the epidemic of antibiotic resistance in *Enterobacteriaceae* include Verona integron-encoded metallo- β -lactamase (VIM), New Delhi metallo- β -lactamase (NDM), imipenemase (IMP), and oxacillinase-48-type (OXA-48) (4, 5). Due to the importance of patient-to-patient transmission of resistant organisms, infection control strategies such as (1) hand hygiene; (2) contact care; (3) following the directions of dedicated hospital personnel infection control policies; (4) environmental sanitation; (5) adherence to decolonization protocols; and (6) establishing monitoring procedures for the diagnosis of asymptomatic patients can be effective as preventive tools (6, 7). Many healthcare facilities propose screening tools for these bacteria. The epidemiological data in every community determine which attendees should be screened. Those admitted directly from long-term acute care institutions and patients admitted from other acute care hospitals should be checked for resistance. Other key indicators to test include hospitalization history (within the previous six months), functional disabilities, and transferring between hospital wards and patients from communities with a high frequency of CRE (8-11).

Although the epidemiological information on CRE in some treatment communities has not been available, it seems necessary to develop the epidemiological model of this type of resistance in each treatment center because this data can be a road map for screening, isolation, and quarantining patients carrying these strains at the beginning of admission to the hospital, which can significantly reduce the transmission of this type of drug resistance between patients and between patients and hospital staff. This strategy seems cost-effective, especially in areas with limited resources. The necessary decisions and measures are taken in each treatment center independently based on the information obtained from epidemiological investigations.

2. Objectives

In this regard, we decided to investigate the prevalence of colonization with *Enterobacteriaceae*, *E. coli*, *Klebsiella*,

and *Enterobacter* resistant to carbapenem and its related risk factors in hospitalized patients in a pediatric referral center in Tehran.

3. Methods

This cross-sectional descriptive study was conducted on 295 stool samples from patients admitted to the hospital for six months in 2021 of which 32% were taken from girls. Patient's age distribution was 2 - 15 years. All patients hospitalized in different wards, except the neonatal and PICU departments, during the first 48 hours of admission were included in the study. The data of anonymous and unverifiable patients (samples with no name on container) were excluded from the study. After obtaining informed consent, a stool sample was taken from patients in the first 48 hours and sent to the Infection Research Center laboratory with a special patient information form. The sample was cultured in EMB or Mackanki agar medium and incubated for 24 - 48 hours at 37°C. After examining the created colonies, a slide was prepared, and after gram staining, the colonies containing gram-negative bacteria were isolated, and differential tests were performed to identify the bacterial strain, and *Enterobacteriaceae* strains were isolated. In the next step, an antibiogram was done in Mueller Hinton agar medium using meropenem and imipenem discs by Kirby-Baure method according to CLSI 2021 protocol. Then carbapenemase genes in carbapenem-resistant strains were investigated by using the PCR method for the presence of carbapenemase genes (*VIM*, *IMP*, *SPM-1*, *NDM-1*, *OXA-48*). Characteristics of primers that were used are shown in the following Table 1.

In order to collect information, a questionnaire was designed for recording data. The Ethics Committee of Shahid Beheshti University approved this study (Ethical code: IR.SBMU.RICH.REC.1400.019).

3.1. Statistical Analysis

Statistical analysis was performed using SPSS software version 22. The quantitative and qualitative variables were indicated as means and number (percentage), respectively.

4. Results

In this study, 295 stool samples were examined, of which 32% were taken from girls. Patient's age distribution was 2 - 15 years and 82% of samples had a positive culture with *Enterobacteriaceae*.

The prevalence of carbapenem resistance among 295 stool samples with a 95% confidence interval (between 31.609-42.629) was reported at 37% with microorganism

Table 1. Primer Characteristics

Gene	Base Pairs	Sequence (5' → 3')	TM (°C)	PCR Conditions	References
OXA-48	392	F: CCAAGCATTTTACC CGCATCKACC	65.5	One cycle of initial denaturation at 95°C for 1 min; 30 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 75°C for 1 min; and one cycle of final extension at 72 for 7 min.	(12)
		R: GYTTGACCATACGCTGRCTGCG	61		
NDM-1	129	F: CCCCCACACACAGTGACANCTC	75.6	One cycle of initial denaturation at 95°C for 1 min; 32 cycles of denaturation at 95°C for 30 s, annealing at 61°C for 30 s, extension at 72°C for 1 min; and one cycle of final extension at 72°C for 5 min.	(13)
		R: GTAGTGCTCAGTGTGGGCAT	63		
VIM	390	F: GATGGTGTGGTTCGCATA	55.5	One cycle of initial denaturation at 94°C for 10 min; 35 cycles of denaturation at 94°C for 30 s, annealing at 61°C for 40 s, extension at 72°C for 1 min; and one cycle of final extension at 72°C for 7 min.	(14)
		R: CGAATGCGCAGACCAG	57.2		
KPC	636	F: CTGCTTGCTCTCATGGCC	60.5	One cycle of initial denaturation at 94°C for 5 min; 32 cycles of denaturation at 94°C for 35 s, annealing at 62°C for 35 s, extension at 72°C for 32 s; and one cycle of final extension at 72°C for 5 min.	(15)
		R: CCTCGCTGTCTGTATCC	62.5		

distribution as: *E. coli* (59.7%), *Klebsiella* (23%), *Enterobacter* (14.6%), *Citrobacter* (2.7%).

The ratio of resistant to non-resistant microorganisms in patients with underlying disease and a history of hospitalization was 0.48 and 0.48, respectively. Also, the ratio of resistant to non-resistant microorganisms in patients with a history of receiving antibiotics was 0.548 (Table 2).

Based on Table 3, the ratio of resistant *Enterobacteriaceae* to the total samples taken in patients with a history of underlying disease was 0.39. The ratio of resistant *Enterobacteriaceae* to the total samples taken from patients with a history of receiving antibiotics and patients with a history of hospitalization was 0.468 and 0.405, respectively.

According to our findings, the most found gene was OXA-48 (56%), followed by IMP (13%) and VIM (13%). The NDM-1 gene was found in three samples (3%), and the SPM gene was not found in any samples. In 32 samples (29.6%) containing resistant *Enterobacteriaceae* (in phenotypic test), none of the examined genes were found, which could indicate the presence of other genes or other resistance mechanisms in these strains.

In 13% of resistant samples, more than one resistance gene was found; VIM, IMP (4), VIM, IMP, OXA-48 (1), IMP, OXA-48 (4), OXA-48, VIM, NDM (3), OXA-48, VIM (3), NDM, OXA-48 (1), NDM, VIM (1).

3

5. Discussion

Although the spread of CRE and the resulting infections as a growing concern is a serious threat to public health worldwide, its prevalence and epidemiologic determinants are still unknown in many settings. Infections caused by these bacteria are associated with significant morbidity and mortality and have limited treatment options. Rapid and accurate diagnosis of carbapenem resistance in these species is important for planning infection control measures (12, 13). Due to the importance of

patient-to-patient transmission of resistant strains, especially through contact with colonized stools in high-risk

patients, in the present study, we aimed to investigate the prevalence of community-acquired colonization with *Enterobacteriaceae*; *E. coli*, *Klebsiella*, and carbapenem-resistant *Enterobacter* to plan the best infection control policies. In this study, the prevalence of carbapenem resistance among stool samples was reported as 37%, and resistance was high in patients with a history of taking antibiotics, a history of frequent hospitalizations, and who had an underlying disease. Among carbapenemase genes, the most found gene was OXA-48, followed by IMP and VIM.

Extensive studies have been conducted in the field of antibiotic resistance patterns in *Enterobacteriaceae*, which have had different results based on the studied population, sample type, sampling time, and antibiotic resistance assessment method. In the study by Solgi et al., which was conducted to investigate the intestinal carriage of CRE and analyze the risk factors for it in hospitalized adults in Iran, the carriage rate of CRE in hospitalized patients was 37.9% (14). The results of this study were similar to the findings of our study, even though the age group of this study was different, and sampling was done at the beginning of hospitalization to find community-acquired colonization (14). In the study of Peymani and Najafipour, which was conducted on samples taken from hospitalized adult patients in intensive care units in Tehran and Qazvin cities, out of 49 colonies of *Enterobacter cloacae* isolated by the standard method, 26 (53.1%) of the colonies had a multiple drug resistance pattern based on the Kirby-Baure method, and 1.4% of them showed resistance to carbapenems (15). The lower prevalence of carbapenem resistance compared to the present study can be due to including only one bacterium from the *Enterobacteriaceae* family in the study, while in the present study, several strains, including *E. coli*, *Klebsiella* and *Enterobacter*, have been investigated in terms of resistance. Moreover, the age group of the study was different. In the study of Shokri et al., a to-

Table 2. The Ratio of Carbapenem-resistant to Non-resistant *Enterobacteriaceae*

Variables	Prevalence (%)	Ratio	Standard Error	95% Confidence Interval
Patients without underlying disease	8	0.366	0.062	0.254 - 0.495
Patients with underlying disease	29	0.486	0.037	0.413 - 0.559
Patients without a history of hospitalization	44	0.368	0.063	0.253 - 0.500
Patients with a history of hospitalization	19	0.483	0.037	0.411 - 0.556
Patients without a history of receiving antibiotics	14	0.356	0.044	0.274 - 0.448
Patients with a history of receiving antibiotics	23	0.548	0.044	0.459 - 0.634

Table 3. The Ratio of Carbapenem-resistant *Enterobacteriaceae* to Total Samples

Variables	Ratio	Standard Error	95% Confidence Interval
Patients without underlying disease	0.285	0.051	0.195 - 0.396
Patients with underlying disease	0.399	0.033	0.335 - 0.465
Patients without a history of hospitalization	0.269	0.050	0.182 - 0.378
Patients with a history of hospitalization	0.405	0.033	0.341 - 0.472
Patients without a history of receiving antibiotics	0.273	0.036	0.207 - 0.350
Patients with a history of receiving antibiotics	0.468	0.041	0.388 - 0.550

tal of 131 strains of *E. coli* and 43 strains of *Enterobacter* were isolated from blood and urine cultures of hospitalized patients, of which 79% and 81% were MDR, and 3.3% of *E. coli* strains and 8.6% of *Enterobacter* strains were insensitive to carbapenems, which was confirmed with the MIC results (16). The difference in the results of Shokri et al. was due to the type of sample and age group studied. In the present study, stool samples were taken, which are different from blood and urine strains in terms of the type of bacterium and the pattern of resistance (16). In the study conducted by Al Fadhli et al. on rectal swabs from ICU patients during the first 48 hours of admission, out of 590 patients who participated, 58 patients were CRE positive, which showed a prevalence of 9.8% in the screened samples (17). Also, in Rai et al.'s study, among the 242 stool samples taken from patients at the beginning of hospitalization, 9.9% carried carbapenemase-containing strains (18). Although most of these studies were conducted on adult patients, the high prevalence of resistant strains in the samples of children in the first 48 hours in our study can be due to several reasons, such as the effect of incorrect prescription of antibiotics in the treatment of infections, non-adherence to antibiotic-stewardship or transmission of resistance genes by various transmitting agents such as plasmids, bacteriophages, transposons and integrons in our community (19).

The frequency of carbapenemase genes has been different in different studies. The most prevalent gene found in this study was *OXA-48*. In Pan et al.'s study, which investigated fecal carriage in outpatient children in Shanghai, the *blaNDM* gene was the main carbapenemase gene found

(20). In Mohan et al.'s study that investigated fecal carriage in hospitalized adult patients in India, among 42 CRE isolates, 22 patients carried *blaNDM-1*, 17 patients had *blaVIM* gene, and no isolates were positive for *blaKPC* and *blaIMP* genes (21). In Solgi et al.'s study, the gene found was *OXA-48*, followed by *blaNDM-1* and *blaNDM-7* (14). In this study, similar to our study, the most common gene was *OXA-48*.

The *OXA-48* resistance gene has been reported in more studies compared to other genes. Various studies confirm that many genes encode the carbapenemase enzyme, whose frequency is different in different communities (22, 23). In the present study, more than one resistance gene was reported in 13% of carbapenem-resistant samples, indicating the presence of different plasmids carrying the resistance gene, which can make the treatment more complicated.

In the current study, a high percentage of resistance was observed in patients with antibiotic use, a history of frequent hospitalizations, and patients with underlying diseases, which is in agreement with the results of the study by Yamamoto et al., who reported longer hospitalizations and a history of antibiotic use as risk factors for carrying CRE (24).

In the study of Tran et al., history of hospitalization and history of treatment with carbapenem were also independent risk factors for colonization with CRE (25). In Asai et al.'s study, the results showed that previous hospitalization within 90 days ($P = 0.006$) and previous antibiotic use within 90 days ($P = 0.005$) were risk factors for acquiring CRE (26). The results of these studies are also consistent

with our study. In the systematic study and meta-analysis by van Loon et al., which was also conducted to investigate the clinical epidemiology of carbapenem-resistant *Enterobacteriaceae*, it was pointed out that the history of using carbapenem and cephalosporins were the most common risk factors associated with the acquisition of CRE (27). In this study, similar to the current study's findings, the underlying disease was also a risk factor for resistance (27).

One of the limitations of the present study could be selecting patients from a tertiary university hospital that includes patients with multiple underlying diseases and a frequent history of receiving antibiotics, so the pattern of resistance in this setting may not be representative of the statistical population of children in our community. But considering the purpose of the study, which was to achieve the epidemiological pattern in this hospital, screening patients by this method can decrease colonization rates in our hospital.

5.1. Conclusions

The present study shows a high level of CRE colonization among hospitalized children, indicating the wide distribution of these strains in the community. In general, the high frequency of strains with drug resistance, such as high resistance to carbapenems, indicates the urgent need to review and modify infection control strategies. Considering the high prevalence of carbapenem resistance genes in stool samples colonized with *Enterobacteriaceae* in our hospital patients, which are located on the plasmids that can be rapidly spread in the hospital environment, it is important for the hospital infection control committee to take preventive measures in order to prevent the spread of these bacteria in our hospital, such as screening stool samples in high-risk patients.

Acknowledgments

We should appreciate all hospital and laboratory staff at Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran, who helped us in conducting this project.

Footnotes

Authors' Contribution: S. A.: Project supervision and reviewing the manuscript draft; L. A.: Supervision of lab tests, reviewing the manuscript draft; A. S.: Methodology consultant; N. T.: Conducting lab tests; G. Sh.: Corresponding author, main researcher.

Conflict of Interests: The authors are employees of Shahid Beheshti University of Medical Sciences.

Data Reproducibility: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: The Ethics Committee of Shahid Beheshti University approved this study (Ethical code: IR.SBMU.RICH.REC.1400.019).

Funding/Support: There is no funding or support.

Informed Consent: Informed consent was signed by all participants.

References

- Magiorakos AP, Suetens C, Monnet DL, Gagliotti C, Heuer OE, E. ARS-Net Coordination Group, et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg? *Antimicrob Resist Infect Control*. 2013;2(1):6. [PubMed ID: 23410479]. [PubMed Central ID: PMC3691711]. <https://doi.org/10.1186/2047-2994-2-6>.
- Gaynes RP, Culver DH. Resistance to imipenem among selected gram-negative bacilli in the United States. *Infect Control Hosp Epidemiol*. 1992;13(1):10-4. [PubMed ID: 1545108]. <https://doi.org/10.1086/646417>.
- Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Bidle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2001;45(4):1151-61. [PubMed ID: 11257029]. [PubMed Central ID: PMC90438]. <https://doi.org/10.1128/AAC.45.4.1151-1161.2001>.
- Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among *Enterobacteriaceae* in Europe. *Clin Microbiol Infect*. 2012;18(5):413-31. [PubMed ID: 22507109]. <https://doi.org/10.1111/j.1469-0691.2012.03821.x>.
- Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis*. 2013;13(9):785-96. [PubMed ID: 23969216]. [PubMed Central ID: PMC4673667]. [https://doi.org/10.1016/S1473-3099\(13\)70190-7](https://doi.org/10.1016/S1473-3099(13)70190-7).
- Barnes SL, Morgan DJ, Harris AD, Carling PC, Thom KA. Preventing the transmission of multidrug-resistant organisms: modeling the relative importance of hand hygiene and environmental cleaning interventions. *Infect Control Hosp Epidemiol*. 2014;35(9):1156-62. [PubMed ID: 2511924]. [PubMed Central ID: PMC4204209]. <https://doi.org/10.1086/677632>.
- Harris AD, Kotetishvili M, Shurland S, Johnson JA, Morris JG, Nemyo LL, et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase *Escherichia coli* acquisition. *Am J Infect Control*. 2007;35(2):97-101. [PubMed ID: 17327188]. <https://doi.org/10.1016/j.ajic.2006.09.011>.
- Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged. The Index of Adl: A Standardized Measure of Biological and Psychosocial Function. *JAMA*. 1963;185:914-9. [PubMed ID: 14044222]. <https://doi.org/10.1001/jama.1963.03060120024016>.
- Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, et al. Recent exposure to antimicrobials and carbapenem-resistant *Enterobacteriaceae*: the role of antimicrobial stewardship. *Infect Control Hosp Epidemiol*. 2012;33(8):817-30. [PubMed ID: 22759550]. [PubMed Central ID: PMC4370272]. <https://doi.org/10.1086/666642>.
- Schwaber MJ, Carmeli Y. Carbapenem-resistant *Enterobacteriaceae*: a potential threat. *JAMA*. 2008;300(24):2911-3. [PubMed ID: 19109119]. <https://doi.org/10.1001/jama.2008.896>.
- Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant *Klebsiella pneumoniae* acquisition among hospitalized adults and effect of acquisition on mortality. *Antimicrob Agents Chemother*. 2008;52(3):1028-

33. [PubMed ID: 18086836]. [PubMed Central ID: PMC2258527]. <https://doi.org/10.1128/AAC.01020-07>.
12. Baran I, Aksu N. Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Turkey. *Ann Clin Microbiol Antimicrob*. 2016;**15**:20. [PubMed ID: 27048322]. [PubMed Central ID: PMC4822248]. <https://doi.org/10.1186/s12941-016-0136-2>.
 13. Kamio K, Espinoza JL. The Predominance of Klebsiella aerogenes among Carbapenem-Resistant Enterobacteriaceae Infections in Japan. *Pathogens*. 2022;**11**(7). [PubMed ID: 35889968]. [PubMed Central ID: PMC9323708]. <https://doi.org/10.3390/pathogens11070722>.
 14. Solgi H, Badmasti F, Aminzadeh Z, Giske CG, Pourahmad M, Vaziri F, et al. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla (NDM-7) and bla (OXA-48). *Eur J Clin Microbiol Infect Dis*. 2017;**36**(11):2127-35. [PubMed ID: 28639165]. <https://doi.org/10.1007/s10096-017-3035-3>.
 15. Peymani A, Najafipour R. Multidrug resistance in Pseudomonas aeruginosa and Enterobacter cloacae isolated from intensive care units of Qazvin and Tehran hospitals. *J Clin Res Paramed Sci*. 2014;**3**(1).
 16. Shokri D, Mobasherizadeh S, Fatemi SM, Moayednia R, Sadeghi Naeeni M. [Hospital based surveillance of carbapenem resistance in multidrug-resistant (MDR) strains of Enterobacter and Escherichia coli in Isfahan]. *Journal of Microbial World*. 2015;**8**(22):64-75. Persian.
 17. Al Fadhli AH, Jamal WY, Rotimi VO. Prevalence of carbapenem-resistant Enterobacteriaceae and emergence of high rectal colonization rates of blaOXA-181-positive isolates in patients admitted to two major hospital intensive care units in Kuwait. *PLoS One*. 2020;**15**(11):e0241971. [PubMed ID: 33201906]. [PubMed Central ID: PMC7671514]. <https://doi.org/10.1371/journal.pone.0241971>.
 18. Rai S, Das D, Niranjana DK, Singh NP, Kaur IR. Carriage prevalence of carbapenem-resistant Enterobacteriaceae in stool samples: A surveillance study. *Australas Med J*. 2014;**7**(2):64-7. [PubMed ID: 24611074]. [PubMed Central ID: PMC3941578]. <https://doi.org/10.4066/AMJ.2014.1926>.
 19. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. *Clin Microbiol Rev*. 2002;**15**(4):647-79. [PubMed ID: 12364374]. [PubMed Central ID: PMC126860]. <https://doi.org/10.1128/CMR.15.4.647-679.2002>.
 20. Pan F, Tian D, Wang B, Zhao W, Qin H, Zhang T, et al. Fecal carriage and molecular epidemiology of carbapenem-resistant Enterobacteriaceae from outpatient children in Shanghai. *BMC Infect Dis*. 2019;**19**(1):678. [PubMed ID: 31370804]. [PubMed Central ID: PMC6670130]. <https://doi.org/10.1186/s12879-019-4298-3>.
 21. Mohan B, Prasad A, Kaur H, Hallur V, Gautam N, Taneja N. Fecal carriage of carbapenem-resistant Enterobacteriaceae and risk factor analysis in hospitalised patients: A single centre study from India. *Indian J Med Microbiol*. 2017;**35**(4):555-62. [PubMed ID: 29405149]. https://doi.org/10.4103/ijmm.IJMM_17_144.
 22. Montagnani C, Prato M, Scollaro C, Colombo S, Tagliabue C, et al. Carbapenem-resistant Enterobacteriaceae Infections in Children: An Italian Retrospective Multicenter Study. *Pediatr Infect Dis J*. 2016;**35**(8):862-8. [PubMed ID: 27100130]. <https://doi.org/10.1097/INF.0000000000001188>.
 23. Folgore L, Livadiotti S, Carletti M, Bielicki J, Pontrelli G, Ciofi Degli Atti ML, et al. Epidemiology and clinical outcomes of multidrug-resistant, gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period. *Pediatr Infect Dis J*. 2014;**33**(9):929-32. [PubMed ID: 24642515]. <https://doi.org/10.1097/INF.0000000000000339>.
 24. Yamamoto N, Asada R, Kawahara R, Hagiya H, Akeda Y, Shanmugakani RK, et al. Prevalence of, and risk factors for, carriage of carbapenem-resistant Enterobacteriaceae among hospitalized patients in Japan. *J Hosp Infect*. 2017;**97**(3):212-7. [PubMed ID: 28736270]. <https://doi.org/10.1016/j.jhin.2017.07.015>.
 25. Tran DM, Larsson M, Olson L, Hoang NTB, Le NK, Khu DTK, et al. High prevalence of colonisation with carbapenem-resistant Enterobacteriaceae among patients admitted to Vietnamese hospitals: Risk factors and burden of disease. *J Infect*. 2019;**79**(2):115-22. [PubMed ID: 31125639]. <https://doi.org/10.1016/j.jinf.2019.05.013>.
 26. Asai N, Sakanashi D, Suematsu H, Kato H, Hagihara M, Nishiyama N, et al. The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: Case control study in a single institute in Japan. *J Infect Chemother*. 2018;**24**(7):505-9. [PubMed ID: 29548627]. <https://doi.org/10.1016/j.jiac.2018.02.005>.
 27. van Loon K, Voor In 't Holt AF, Vos MC. A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae. *Antimicrob Agents Chemother*. 2018;**62**(1). [PubMed ID: 29038269]. [PubMed Central ID: PMC5740327]. <https://doi.org/10.1128/AAC.01730-17>.